Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LDL-C Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

NCT01617655
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Sep 13, 2026, 9:32 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

NCT04798430
View directory record Official record
Conditions
Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
10 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Evanston, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

NCT01380730
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo to Evolocumab
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
55
States / cities
Birmingham, Alabama • Tucson, Arizona • Malvern, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)

NCT04929249
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Greenwich, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

NCT06742853
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of Long Term Evaluation Against LDL-C Trial

NCT01439880
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Standard of care
Biological · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
78
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 13, 2026, 9:32 PM EDT
Active, not recruiting Phase 3 Interventional

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

NCT05360446
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Inclisiran sodium 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085
View directory record Official record
Conditions
Healthy Volunteers, Hypercholesterolemia
Interventions
LY3015014, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

NCT05425745
View directory record Official record
Conditions
Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Lipid Metabolism Disorder, Metabolic Disease, Lipid Metabolism, Inborn Errors, Genetic Disease, Inborn, Hyperlipoproteinemias
Interventions
Obicetrapib, Placebo
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
20
States / cities
Jonesboro, Arkansas • Toluca Lake, California • Sarasota, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 13, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Pelacarsen, Placebo, Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 13, 2026, 9:32 PM EDT
Recruiting Not applicable Interventional

Impact of the Corrie Lipids Digital Health Program on Lipid Optimization

NCT07478887
View directory record Official record
Conditions
Cardiovascular Risk, LDL-C, Lipids, Digital Health, Implementation Science
Interventions
Corrie Lipids Digital Health Program
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D on Lipids

NCT00723385
View directory record Official record
Conditions
Hypercholesterolemia, Vitamin D Deficiency
Interventions
Vitamin D (1000 or 2000 IU/day), Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

NCT02739984
View directory record Official record
Conditions
Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
Interventions
Evolocumab, Placebo to Evolocumab
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
46
States / cities
Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 13, 2026, 9:32 PM EDT
Recruiting Not applicable Interventional

A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients

NCT06571162
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Clinical Pharmacy Team, Usual Care
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Not applicable Interventional Results available

(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

NCT00526058
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Secura then Futura, Futura then Secura
Device
Lead sponsor
B. Braun Medical Inc.
Industry
Eligibility
25 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Hartford, Connecticut • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

NCT03814187
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran Sodium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
141
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

NCT02514070
View directory record Official record
Conditions
Lipoprotein Metabolism, PCSK9, Proteomics
Interventions
EPA-rich fish oil, DHA-rich fish oil
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

NCT03531905
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
Interventions
Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 13, 2026, 9:32 PM EDT
Not listed Phase 3 Interventional

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

NCT04797247
View directory record Official record
Conditions
Cardiovascular Diseases, Hyper-LDL-cholesterolemia
Interventions
lerodalcibep
Drug
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

NCT04790513
View directory record Official record
Conditions
Hypercholesterolemia, Cardiovascular Diseases
Interventions
lerodalcibep, evolocumab, alirocumab
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

NCT00137462
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 3 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00050479
View directory record Official record
Conditions
Macular Degeneration
Interventions
Celecoxib (Celebrex)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 13, 2026, 9:32 PM EDT
Completed Phase 2 Interventional

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

NCT00810979
View directory record Official record
Conditions
Hyperlipidemia
Interventions
SLx-4090, Placebo, Statin
Drug · Other
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 13, 2026, 9:32 PM EDT